In the LIBRETTO-001 trial, LOXO-292 has shown marked antitumor activity in RET fusion-positive NSCLC, both in pretreated and treatment naïve patients ORR was 68% and CNS ORR was 91% in chemotherapy pretreated patients; ORR was 85% in treatment naïve patients. This evidence concerns the gene RET and non-small cell lung carcinoma.